AbbVie announces availability of new advanced Parkinson's treatment in Canada
21st April 2014
AbbVie has announced that a new treatment called Duodopa (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson’s disease.
Duodopa is approved in Canada for the management of advanced Parkinson’s disease in adults with severe, disabling motor fluctuations and hyper-/dyskinesia (involuntary movements) not satisfactorily controlled by combinations of available oral medicinal products for Parkinson’s disease.
Read more at source article www.manufacturing.pharmaceutical-business-review.com